447 related articles for article (PubMed ID: 30509142)
1. Clinical Development of Biologics Approved by the US Food and Drug Administration, 2003-2016.
Alexander GC; Ogasawara K; Wiegand D; Lin D; Breder CD
Ther Innov Regul Sci; 2019 Nov; 53(6):752-758. PubMed ID: 30509142
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinical Trials Supporting US Food and Drug Administration Approval of Novel Therapeutic Agents, 1995-2017.
Zhang AD; Puthumana J; Downing NS; Shah ND; Krumholz HM; Ross JS
JAMA Netw Open; 2020 Apr; 3(4):e203284. PubMed ID: 32315070
[TBL] [Abstract][Full Text] [Related]
3. The US Food and Drug Administration's expedited approval programs: Evidentiary standards, regulatory trade-offs, and potential improvements.
Wallach JD; Ross JS; Naci H
Clin Trials; 2018 Jun; 15(3):219-229. PubMed ID: 29871509
[TBL] [Abstract][Full Text] [Related]
4. FDA Approval and Regulation of Pharmaceuticals, 1983-2018.
Darrow JJ; Avorn J; Kesselheim AS
JAMA; 2020 Jan; 323(2):164-176. PubMed ID: 31935033
[TBL] [Abstract][Full Text] [Related]
5. Use of US Food and Drug Administration Expedited Drug Development and Review Programs by Orphan and Nonorphan Novel Drugs Approved From 2008 to 2021.
Monge AN; Sigelman DW; Temple RJ; Chahal HS
JAMA Netw Open; 2022 Nov; 5(11):e2239336. PubMed ID: 36318210
[TBL] [Abstract][Full Text] [Related]
6. Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study.
Kesselheim AS; Wang B; Franklin JM; Darrow JJ
BMJ; 2015 Sep; 351():h4633. PubMed ID: 26400751
[TBL] [Abstract][Full Text] [Related]
7. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
8. Expedited Programs for Serious Conditions: An Update on Breakthrough Therapy Designation.
Kwok M; Foster T; Steinberg M
Clin Ther; 2015 Sep; 37(9):2104-20. PubMed ID: 26297571
[TBL] [Abstract][Full Text] [Related]
9. Patient Participation in Clinical Trials of Oncology Drugs and Biologics Preceding Approval by the US Food and Drug Administration.
Hutchinson N; Carlisle B; Doussau A; Bosan R; Gumnit E; MacPherson A; Fergusson DA; Kimmelman J
JAMA Netw Open; 2021 May; 4(5):e2110456. PubMed ID: 34003270
[TBL] [Abstract][Full Text] [Related]
10. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
11. Safety related label changes for new drugs after approval in the US through expedited regulatory pathways: retrospective cohort study.
Mostaghim SR; Gagne JJ; Kesselheim AS
BMJ; 2017 Sep; 358():j3837. PubMed ID: 28882831
[No Abstract] [Full Text] [Related]
12. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Supportive Evidence for US Food and Drug Administration Approvals of Novel Drugs in 2020.
Mitra-Majumdar M; Gunter SJ; Kesselheim AS; Brown BL; Joyce KW; Ross M; Pham C; Avorn J; Darrow JJ
JAMA Netw Open; 2022 May; 5(5):e2212454. PubMed ID: 35579897
[TBL] [Abstract][Full Text] [Related]
14. Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.
Puthumana J; Miller JE; Kim J; Ross JS
JAMA Netw Open; 2018 Jun; 1(2):e180283. PubMed ID: 30646072
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of Clinical Studies Used for US Food and Drug Administration Supplemental Indication Approvals of Drugs and Biologics, 2017 to 2019.
Dhodapkar M; Zhang AD; Puthumana J; Downing NS; Shah ND; Ross JS
JAMA Netw Open; 2021 Jun; 4(6):e2113224. PubMed ID: 34110392
[TBL] [Abstract][Full Text] [Related]
16. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer.
Kesselheim AS; Myers JA; Avorn J
JAMA; 2011 Jun; 305(22):2320-6. PubMed ID: 21642684
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of Trials Associated With Drugs Approved by the Food and Drug Administration in 2015 and 2016.
Eckert JC
Med Care; 2020 Mar; 58(3):194-198. PubMed ID: 32106163
[TBL] [Abstract][Full Text] [Related]
18. Development times, clinical testing, postmarket follow-up, and safety risks for the new drugs approved by the US food and drug administration: the class of 2008.
Moore TJ; Furberg CD
JAMA Intern Med; 2014 Jan; 174(1):90-5. PubMed ID: 24166236
[TBL] [Abstract][Full Text] [Related]
19. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
20. Participation of women and sex analyses in late-phase clinical trials of new molecular entity drugs and biologics approved by the FDA in 2007-2009.
Poon R; Khanijow K; Umarjee S; Fadiran E; Yu M; Zhang L; Parekh A
J Womens Health (Larchmt); 2013 Jul; 22(7):604-16. PubMed ID: 23768021
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
